title: Effect of antibiotics on clinical, pathologic and immunologic responses in murine Potomac horse fever: protective effects of doxycycline.
abstract: Effects of three antibiotics on clinical, pathologic and immunologic responses in murine Potomac horse fever caused by Ehrlichia risticii infection were examined. When antibiotics were given after the development of clinical signs, antibiotics ranked in the order of reducing clinical signs and in preventing body weight loss and an intestinal enlargement were doxycycline, demeclocycline and rifampin. Infected mice treated with doxycycline and demeclocycline developed greater splenomegaly than rifampin-treated or untreated infected mice. All antibiotics used prevented thymic atrophy due to E. risticii infection. Indirect fluorescent antibody titers were highest with doxycycline treatment. Mice treated with demeclocycline and rifampin produced higher antibody titer than those without treatment. Ehrlichia risticii was reisolated from the spleens of both untreated and rifampin-treated infected mice. The effects of administering single doses of doxycycline at different times after infection were examined. Body weight loss was prevented by the drug given at every treatment day examined, i.e. Days 3, 5 and 7 post-infection (PI). Thymic atrophy was minimum in mice treated at Day 5 PI, while splenomegaly was found on every treatment day. Splenocyte proliferative response to concanavalin A and lipopolysaccharide, and specific antibody development against E. risticii was best in mice treated at Day 5 PI followed by those treated at Day 3 and Day 7 PI.
authors.affiliation: Department of Veterinary Pathobiology, College of Veterinary Medicine, Ohio State University, Columbus 43210-1092.
authors.forename: Y
authors.initials: Y
authors.lastname: Rikihisa
authors.forename: B M
authors.initials: BM
authors.lastname: Jiang
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D003707:Demeclocycline / Q000627:therapeutic use; D004318:Doxycycline / Q000494:pharmacology / Q000627:therapeutic use*; D004536:Ehrlichia / Q000276:immunology; D005260:Female; D005455:Fluorescent Antibody Technique; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D008213:Lymphocyte Activation; D051379:Mice; D009929:Organ Size / Q000187:drug effects; D012288:Rickettsiaceae Infections / Q000188:drug therapy / Q000662:veterinary*; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use*; D013163:Splenomegaly; D013950:Thymus Gland / Q000187:drug effects; D015431:Weight Loss / Q000187:drug effects
chemical_list: D000907:Antibodies, Bacterial; D003707:Demeclocycline; D004318:Doxycycline; D012293:Rifampin